The estimated Net Worth of Deepak Chadha is at least $664 mil dollars as of 18 May 2021. Mr Chadha owns over 15,200 units of Brickell Biotech Inc stock worth over $183,692 and over the last 5 years he sold BBI stock worth over $0. In addition, he makes $479,833 as Chief R&D Officer at Brickell Biotech Inc.
Mr has made over 3 trades of the Brickell Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,200 units of BBI stock worth $12,616 on 18 May 2021.
The largest trade he's ever made was buying 26,087 units of Brickell Biotech Inc stock on 22 June 2020 worth over $61,304. On average, Mr trades about 9,470 units every 47 days since 2020. As of 18 May 2021 he still owns at least 78,167 units of Brickell Biotech Inc stock.
You can see the complete history of Mr Chadha stock trades at the bottom of the page.
Deepak Chadha is the Chief R&D Officer at Brickell Biotech Inc.
As the Chief R&D Officer of Brickell Biotech Inc, the total compensation of Mr Chadha at Brickell Biotech Inc is $479,833. There are 2 executives at Brickell Biotech Inc getting paid more, with Vijay Samant having the highest compensation of $1,464,000.
Mr Chadha is 51, he's been the Chief R&D Officer of Brickell Biotech Inc since . There are 12 older and 5 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
Deepak's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi, eGary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: